 | Up a level |
Cramer, Paula, von Tresckow, Julia, Robrecht, Sandra, Bahlo, Jasmin, Furstenau, Moritz 
ORCID: 0000-0002-6593-0140, Langerbeins, Petra, Pflug, Natali, Al-Sawaf, Othman ORCID: 0000-0001-9895-0570, Heinz, Werner J., Vehling-Kaiser, Ursula, Durig, Jan, Tausch, Eugen, Hensel, Manfred, Sasse, Stephanie, Fink, Anna-Maria, Fischer, Kirsten, Kreuzer, Karl-Anton, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael
(2021).
Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO).
Haematologica, 106 (2).
S. 543 - 555.
PAVIA:
FERRATA STORTI FOUNDATION.
ISSN 0390-6078
Al-Sawaf, Othman ORCID: 0000-0001-9895-0570, Gentile, Brittany ORCID: 0000-0002-6302-5593, Devine, Jacob, Zhang, Can, Sail, Kavita, Tandon, Maneesh, Fink, Anna-Maria, Kutsch, Nadine, Wendtner, Clemens-Martin, Eichhorst, Barbara, Hallek, Michael and Fischer, Kirsten
(2021).
Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
Am. J. Hematol., 96 (9).
S. 1112 - 1120.
HOBOKEN:
WILEY.
ISSN 1096-8652
Al-Sawaf, Othman ORCID: 0000-0001-9895-0570, Seymour, John F., Kater, Arnon P. and Fischer, Kirsten
(2021).
Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?
Hematol. Oncol. Clin. North Am., 35 (4).
S. 775 - 792.
PHILADELPHIA:
W B SAUNDERS CO-ELSEVIER INC.
ISSN 1558-1977